Beyond cytokinesis: The emerging roles of CEP55 in tumorigenesis

Oncogene

Volumn 35, Issue 6, 2016, Pages 683-6390

  Jeffery, J ^a   Sinha, D ^a,b   Srihari, S ^c   Kalimutho, M ^a   Khanna, K K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA B KINASE; BIOLOGICAL MARKER; CANCER VACCINE; CYCLIN B1; ESCRT PROTEIN; EXOCYST; HETERODIMER; HOMODIMER; INDUCIBLE NITRIC OXIDE SYNTHASE; OSTEOPONTIN; PERICENTRIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN; PROTEIN CEP55; PROTEIN FOXM1; PROTEIN P53; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CEP55 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE;

BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CYTOKINESIS; EXOSOME; GENE OVEREXPRESSION; GERM CELL; HINGE REGION; HUMAN; INTRADUCTAL CARCINOMA; LUNG CANCER; MOUTH CARCINOMA; MULTIPLE CANCER; NASOPHARYNX CARCINOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE TONE; STOMACH CARCINOMA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CANCER STEM CELL; CHEMISTRY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; CARCINOGENESIS; CELL CYCLE PROTEINS; CYTOKINESIS; GERM CELLS; HUMANS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES;

EID: 84958034823     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.128     Document Type: Review

References (92)

1. Fabbro M, Zhou BB, Takahashi M, Sarcevic B, Lal P, Graham ME et al. Cdk1/Erk2-and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell 2005; 9: 477-488.
2. Carlton JG, Martin-Serrano J. Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery. Science 2007; 316: 1908-1912.
3. Carlton JG, Agromayor M, Martin-Serrano J. Differential requirements for Alix and ESCRT-III in cytokinesis and HIV-1 release. Proc Natl Acad Sci USA 2008; 105: 10541-10546.
4. Lee HH, Elia N, Ghirlando R, Lippincott-Schwartz J, Hurley JH. Midbody targeting of the ESCRT machinery by a noncanonical coiled coil in CEP55. Science 2008; 322: 576-580.
5. Green RA, Paluch E, Oegema K. Cytokinesis in animal cells. Annu Rev Cell Dev Biol 2012; 28: 29-58.
6. Mierzwa B, Gerlich DW. Cytokinetic abscission: molecular mechanisms and temporal control. Dev Cell 2014; 31: 525-538.
7. Kumar A, Rajendran V, Sethumadhavan R, Purohit R. CEP proteins: the knights of centrosome dynasty. Protoplasma 2013; 250: 965-983.
8. Takahashi M, Yamagiwa A, Nishimura T, Mukai H, Ono Y. Centrosomal proteins CG-NAP and kendrin provide microtubule nucleation sites by anchoring ?-tubulin ring complex. Mol Biol Cell 2002; 13: 3235-3245.
9. Martinez-Garay I, Rustom A, Gerdes HH, Kutsche K. The novel centrosomal associated protein CEP55 is present in the spindle midzone and the midbody. Genomics 2006; 87: 243-253.
10. Sauer G, Korner R, Hanisch A, Ries A, Nigg EA, Sillje HHW. Proteome analysis of the human mitotic spindle. Mol Cell Proteom 2005; 4: 35-43.
11. Zhao WM, Seki A, Fang G. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol Biol Cell 2006; 17: 3881-3896.
12. Mondal G, Rowley M, Guidugli L, Wu J, Pankratz VS, Couch FJ. BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev Cell 2012; 23: 137-152.
13. Neto H, Kaupisch A, Collins LL, Gould GW. Syntaxin 16 is a master recruitment factor for cytokinesis. Mol Biol Cell 2013; 24: 3663-3674.
14. Morita E, Sandrin V, Chung HY, Morham SG, Gygi SP, Rodesch CK et al. Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. Embo J 2007; 26: 4215-4227.
15. Gromley A, Yeaman C, Rosa J, Redick S, Chen C-T, Mirabelle S et al. Centriolin anchoring of exocyst and snare complexes at the midbody is required for secretory-vesicle-mediated abscission. Cell 2005; 123: 75-87.
16. Lekomtsev S, Guizetti J, Pozniakovsky A, Gerlich DW, Petronczki M. Evidence that the tumor-suppressor protein BRCA2 does not regulate cytokinesis in human cells. J Cell Sci 2010; 123: 1395-1400.
17. Guizetti J, Schermelleh L, Mantler J, Maar S, Poser I, Leonhardt H et al. Cortical constriction during abscission involves helices of ESCRT-III-dependent filaments. Science 2011; 331: 1616-1620.
18. Morita E, Colf LA, Karren MA, Sandrin V, Rodesch CK, Sundquist WI. Human ESCRTIII and VPS4 proteins are required for centrosome and spindle maintenance. Proc Natl Acad Sci USA 2010; 107: 12889-12894.
19. van der Horst A, Khanna KK. The peptidyl-prolyl isomerase Pin1 regulates cytokinesis through Cep55. Cancer Res 2009; 69: 6651-6659.
20. van der Horst A, Simmons J, Khanna KK. Cep55 stabilization is required for normal execution of cytokinesis. Cell Cycle 2009; 8: 3742-3749.
21. Bastos RN, Barr FA. Plk1 negatively regulates Cep55 recruitment to the midbody to ensure orderly abscission. J Cell Biol 2010; 191: 751-760.
22. St-Denis N, Gupta GD, Lin ZY, Gonzalez-Badillo B, Pelletier L, Gingras A-C. Myotubularin-related proteins 3 & 4 interact with PLK1 and CEP55 to control CEP55 recruitment to the midbody and ensure proper abscission. Mol Cell Proteom 2015; 14: 946-960.
23. Greenbaum MP, Iwamori T, Buchold GM, Matzuk MM. Germ cell intercellular bridges. Cold Spring Harb Perspect Biol 2011; 3: a005850.
24. Chang YC, Chen YJ, Wu CH, Wu YC, Yen TC, Ouyang P. Characterization of centrosomal proteins Cep55 and pericentrin in intercellular bridges of mouse testes. J Cell Biochem 2010; 109: 1274-1285.
25. Iwamori T, Iwamori N, Ma L, Edson MA, Greenbaum MP, Matzuk MM. TEX14 interacts with CEP55 to block cell abscission. Mol Cell Biol 2010; 30: 2280-2292.
26. Greenbaum MP, Yan W, Wu M-H, Lin Y-N, Agno JE, Sharma M et al. TEX14 is essential for intercellular bridges and fertility in male mice. Proc Natl Acad Sci USA 2006; 103: 4982-4987.
27. Kuo TC, Chen CT, Baron D, Onder TT, Loewer S, Almeida S et al. Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol 2011; 13: 1214-1223.
28. Ettinger AW, Wilsch-Brauninger M, Marzesco A-M, Bickle M, Lohmann A, Maliga Z et al. Proliferating versus differentiating stem and cancer cells exhibit distinct midbody-release behaviour. Nat Commun 2011; 2: 503.
29. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200: 373-383.
30. Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr OpinCell Biol 2009; 21: 575-581.
31. Zhang H-G, Grizzle W. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011; 17: 959-964.
32. Azmi A, Bao B, Sarker F. exosomes in cancer development, metastasis and drug resistance: a comprehensive review. Cancer Metastasis Rev 2013; 32: 623-642.
33. Hong B, Cho J-H, Kim H, Choi E-J, Rho S, Kim J et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009; 10: 556.
34. Hemmings BA, Restuccia DF. PI3K-PKB/Akt Pathway. Cold Spring Harb Perspect Biol 2012; 4: a011189.
35. Manning BD, Cantley LC. AKT/PKB Signaling: Navigating Downstream. Cell 2007; 129: 1261-1274.
36. Cheung M, Testa J. Diverse mechanisms of AKT pathway activation in human maligancy. Curr Cancer Drug Targets 2013; 13: 234-244.
37. Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, Tsou AP et al. FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene 2007; 26: 4272-4283.
38. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC et al. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One 2009; 4: e5052.
39. Hwang CF, Shiu LY, Su LJ, Yu-Fang Y, Wang WS, Huang SC et al. Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis. PLoS One 2013; 8: e84218.
40. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13: 871-882.
41. Yanagisawa H, Schluterman M, Brekken R. Fibulin-5 an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal 2009; 3: 337-347.
42. Jeffery J, Neyt C, Moore W, Paterson S, Bower NI, Chenevix-Trench G et al. Cep55 regulates embryonic growth and development by promoting Akt stability in zebrafish. FASEB J. e-pub ahead of print.
43. Tsai C-Y, Chen C-H, Chang AYW, Chan JYH, Chan SHH. Upregulation of FLJ10540, a PI3K-association protein, in rostral ventrolateral medulla impairs brain stem cardiovascular regulation during mevinphos intoxication. Biochem Pharmacol 2015; 93: 34-41.
44. Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol 2014; 35: 4389-4399.
45. Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 2010; 46: 536-542.
46. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009; 4: e4849.
47. Laoukili J, Kooistra M, Bras A, Kauw J, Kerkhoven R, Morrison A et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136.
48. Laoukili J, Stahl M, Medema RH. FoxM1: At the crossroads of ageing and cancer. Biochim Biophys Acta 2007; 1775: 92-102.
49. Myatt SS, Lam EWF. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-859.
50. Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 2009; 28: 2723-2737.
51. Kato K, Hara A, Kuno T, Kitaori N, Huilan Z, Mori H et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol 2005; 131: 340-346.
52. Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 2008; 10: 1076-1082.
53. Chang YC, Wu CH, Yen TC, Ouyang P. Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1). J Biol Chem 2012; 287: 4376-4385.
54. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
55. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-3212.
56. Pandit B, Halasi M, Gartel AL. p53 negatively regulates expression of FoxM1. Cell Cycle 2009; 8: 3425-3427.
57. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell cycle 2010; 9: 4200-4212.
58. Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999; 96: 2147-2152.
59. Kruger T, Miller A, Godwin A, Wang J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol 2014; 89: 330-341.
60. Chen CH, Shiu LY, Su LJ, Huang CY, Huang SC, Huang CC et al. FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway. J Transl Med 2012; 10: 93.
61. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-1048.
62. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013; 23: 48-62.
63. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011; 12: 245-255.
64. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 2007; 27: 1554-1561.
65. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730-5739.
66. Cheng W-Y, Yang T-HO, Anastassiou D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 2013; 9: e1002920.
67. Al-Ejeh F, Simpson PT, Sanus JM, Klein K, Kalimutho M, Shi W et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 2014; 3: e100.
68. Ma X-J, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974-5979.
69. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 2006; 26: 1507-1516.
70. Hu Y, Wu G, Rusch M, Lukes L, Buetow KH, Zhang J et al. Integrated cross-species transcriptional network analysis of metastatic susceptibility. Proc Natl Acad Sci USA 2012; 109: 3184-3189.
71. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in er-positive and er-negative breast cancers. Clin Cancer Res 2011; 17: 2591-2601.
72. Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One 2013; 8: e63204.
73. Chen D-T, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R et al. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat 2010; 119: 335-346.
74. Martin KJ, Magee D, Fournier MV Gene expression signature as a predictor of chemotherapeutic response in breast cancer. USA 2010; PCT/US2011/039325.
75. Carter SL, Szallasi Z, Eklund A. Prognosis indicators for solid human tumors. USA 2005; PCT/US2006/047662.
76. Perou CM, Bernard PS, Nielsen TO, Ellis MJ, Parker JS, Martin M et al. Methods of Treating Breast Cancer With Taxane Therapy. USA 2012; PCT/US2012/067317.
77. Wagner S, Stone S, Gutin A, Reid J. Gene signatures for lung cancer prognosis and therapy selection. USA 2011; PCT/US2012/051447.
78. Stone S, Gutin A, Wagner S, Reid J. Gene signatures for cancer diagnosis and prognosis. USA 2010; PCT/US2011/049760.
79. Chen DT, Yeatman TJ. Malignancy-risk signature from histologically normal breast tissue. USA 2011; PCT/US2009/030778.
80. Anastassiou D, Cheng W. Biomolecular events in cancer revealed by attractor metagenes. USA 2012; PCT/US2013/037720.
81. Perou CM, Parker JS, Marron JS, Nobel A, Bernard PS, Ellis M et al. Gene expression profiles to predict breast cancer outcomes. USA 2008; PCT/US2009/045820.
82. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P et al. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer . Cancer Res 2006; 66: 7095-7102.
83. Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 2008; 3: e2994.
84. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anticancer drugs. Oncogene 2003; 22: 2192-2205.
85. Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene 2005; 25: 480-486.
86. Singh PK, Srivastava AK, Rath SK, Dalela D, Goel MM, Bhatt ML. Expression and clinical significance of centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma. Immunobiology 2014; 220: 103-108.
87. Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E et al. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009; 32: 474-485.
88. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 2011; 5: 164-182.
89. Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol 2011; 178: 1805-1813.
90. Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E et al. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol 2011; 90: 55-60.
91. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2008; 113: 66-74.
92. Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001; 194: 1313-1324.